drugset

drugset / Trial / NCT07519070

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of HSK44459 Tablets in Patients With Idiopathic Pulmonary Fibrosis

NCT07519070 ↗

Phase 3 Not yet recruiting 420 enrolled Haisco Pharmaceutical Group Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to evaluate the efficacy and safety of HSK44459 tablets in patients with idiopathic pulmonary fibrosis (IPF).

Timeline

Start: 2026-04-05
Primary completion: 2028-04-05
Completion: 2028-12-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HSK44459	Unknown	—	—

Indications